#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Medullary thyroid cancer Rosai-Dorfman syndrome Gastroenteropancreatic neuroendocrine tumour disease Anti-HLA antibody test positive Marginal zone lymphoma refractory Alagille syndrome Optic glioma Dermatomyositis Spinal muscular atrophy Oesophageal squamous cell carcinoma stage II Retinopathy proliferative Scleroderma associated digital ulcer Cryoglobulinaemia Mitochondrial encephalomyopathy Epilepsy More trials…

    Learn about Rare Diseases

    Ocular melanoma Medulloblastoma recurrent – Basic Information Familial haemophagocytic lymphohistiocytosis – Treatment Paroxysmal nocturnal haemoglobinuria – Life with Disease Usher’s syndrome – Basic Information Haemophilia A without inhibitors Noonan syndrome – Basic Information Chronic granulomatous disease – Diagnostics Hyperoxaluria Sarcoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Adg126 Bay 2927088 Vepdegestrant Potassium Canrenoate Other Immunosuppressants Sodium Lactate Solution Gsk6097608 Citric Acid Abc-16F-116 Levocabastine Hydrochloride Protein C SOFTISAN 378 Ecoo6A Milnacipran Hydrochloride Cabergoline ANTIMETABOLITES Ciltacabtagene Autoleucel Danicopan Lamotrigine Gskvx000000014593 More therapies…

    Learn about Your Condition

    Glanzmann's disease Necrotising myositis Vulvovaginal pain Follicular thyroid cancer Mitochondrial DNA depletion Cushing's syndrome Endometrial cancer metastatic Adenocarcinoma pancreas Methylmalonic acidaemia End stage renal disease Lip and/or oral cavity cancer Mixed-type liposarcoma Pathogen resistance Dyspnoea Arteriovenous malformation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Phase 1/2 First‑in‑Human Study of Oral GSK5471713B in Adults with Metastatic Castration‑Resistant Prostate Cancer

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Prostate cancer
    France The Netherlands Spain

  • Efficacy and safety of eplontersen sodium plus ALXN2220 in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM)

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Cardiac amyloidosis
    Investigated Drugs:
    • Alxn2220
    France Germany Italy Spain Sweden

  • Assessing Hemodynamic Effect and Safety of TX000045 in Adults with Pulmonary Hypertension Secondary to Interstitial Lung Disease

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    • TX000045
    Poland Romania Spain

  • Randomized study of ketotifen nasal spray (0.025% and 0.050%) versus sodium cromoglicate nasal spray in patients with rhinitis

    Not yet recruiting

    2 1 1
    Investigated Drugs:
    • Sodium Cromoglicate
    Greece

  • Fosfomycin versus drug combination for oral step‑down treatment of febrile urinary tract infections caused by E. coli in men

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Escherichia urinary tract infection
    Investigated Drugs:
    • Fosfomycin
    • Tolu Balsam
    • Ciprofloxacin
    France

  • Study of neoadjuvant intratumoral ipilimumab combined with systemic nivolumab in patients with locally advanced resectable oral cavity squamous cell carcinoma

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    The Netherlands
Previous Page
1 … 676 677 678 679 680 … 1,657
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!